Abstract
This pictorial introduction to homocysteine illustrates at a glance the nature of homocysteine and its role in cardiovascular disease by means of eight simple figures and an essential bibliography. Homocysteine is a sulfur-containing metabolite of methionine. Conversion back to methionine or transsulfuration to cysteine are the two major metabolic pathways that reduce total homocysteine (tHcy) concentrations in cells and blood. B vitamins are essential cofactors in homocysteine metabolism. Median fasting total homocysteine levels in adult males are ∼10 µmol/L. Increased plasma tHcy concentrations are found with methionine-rich diets, low vitamin B intake, male gender, age, impaired renal function, and genetically determined defects of the enzymes involved in homocysteine metabolism. An inverse relation exists between plasma tHcy and circulating folate or vitamin B6 concentrations, and folic acid supplements of 0.5 mg/d can reduce tHcy levels by ∼25%. Homocystinuric patients, who have severe hyperhomocysteinemia, die prematurely of atherothrombotic disease. Many (but not all) cross-sectional and prospective studies indicate, on average, that plasma tHcy levels <.10 µmol/L are associated with, or predict the development of, coronary, cerebral, and peripheral vascular disease. The risk conferred by hyperhomocysteinemia is graded and is independent of traditional risk factors, with an estimated odds ratio for ischemic heart disease of 1.4 for every 5 µmol/L increase in plasma tHcy. In vitro and in vivo, tHcy has been found to impair endothelial function. It is now well established that tHcy represents a marker of current or subsequent ischemic vascular disease. However, irrefutable proof that hyperhomocysteinemia actually causes atherothrombosis will come only if interventions to lower plasma tHcy will produce concomitant reductions in cardiovascular events.
Similar content being viewed by others
References
Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042–1050.
Dudman NPB, Guo XW, Gordon RB, Dawson PA, Wilcken DEL. Human homocysteine catabolism: Three major pathways and their relevance to development of arterial occlusive disease. J Nutr 1996;126:1295S–1300S.
Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: Methods and clinical applications. Clin Chem 1993;39:1764–1779.
Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable bene~ts of increasing folic acid intakes. JAMA 1995;274:1049–1057.
Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992;12:279–298.
McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111–128.
Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230–236.
Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775–1781.
Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH, for the MRFIT Research Group. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997;17:1947–1953.
Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998;98:204–210.
Arnesen E, Refsum H, Bønaa KH, Ueland PM, Førde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704–790.
Brattström L, Wilcken DEL, Öhrvik J, Brudin L. The common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to cardiovascular disease. Result of a meta-analysis. Circulation 1999;98: 2520–2526.
Robinson K, Arheart K, Refsum H et al. for the European COMAC Group. Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998;97: 437–443.
Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. Br Med 1998;316: 894–898.
D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90:1–11.
Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;96:2542–2544.
Rosenberg LE. Inherited disorders of amino acid metabolism. In: Harrison's Principles of Internal Medicine. New York: McGraw-Hill 1991:1873–1875.
Omenn GS, Beresford SAA, Motulsky AG. Preventing coronary heart disease. B vitamins and homocysteine. Circulation 1998;97:421–424.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Andreotti, F., Burzotta, F., Manzoli, A. et al. Homocysteine and Risk of Cardiovascular Disease. J Thromb Thrombolysis 9, 13–21 (2000). https://doi.org/10.1023/A:1018675624181
Issue Date:
DOI: https://doi.org/10.1023/A:1018675624181